

Date:

(Filing No. H-)

HEALTH COVERAGE, INSURANCE AND FINANCIAL SERVICES

Reproduced and distributed under the direction of the Clerk of the House.

STATE OF MAINE HOUSE OF REPRESENTATIVES 132ND LEGISLATURE FIRST SPECIAL SESSION

COMMITTEE AMENDMENT “ ” to H.P. 111, L.D. 178, “An Act Regarding Coverage for Step Therapy for Advanced Metastatic Cancer”

Amend the bill by striking out the title and substituting the following:

'An Act Regarding Coverage for Step Therapy for Metastatic Cancer'

Amend the bill by striking out everything after the enacting clause and inserting the following:

'Sec. 1. 24-A MRSA §4320-N, sub-§1, ¶A-1 is enacted to read:

A-1. "Associated conditions" means the symptoms or side effects associated with metastatic cancer or its treatment and that, in the judgment of the health care practitioner, further jeopardize the health of a patient if left untreated.

Sec. 2. 24-A MRSA §4320-N, sub-§1, ¶C-1 is enacted to read:

C-1. "Metastatic cancer" means cancer that has spread from the primary or original site of the cancer to nearby tissues, lymph nodes or other areas or parts of the body.

Sec. 3. 24-A MRSA §4320-N, sub-§8 is enacted to read:

8. Step therapy for metastatic cancer and associated conditions prohibited.
Notwithstanding subsection 6, paragraph B, with respect to coverage of a prescription drug on a carrier's formulary for the treatment of metastatic cancer and associated conditions, a carrier or utilization review organization may not require that the enrollee use a step therapy protocol before the carrier provides coverage of a prescription drug approved by the United States Food and Drug Administration.

Sec. 4. Appropriations and allocations. The following appropriations and allocations are made.

**ADMINISTRATIVE AND FINANCIAL SERVICES, DEPARTMENT OF
Departments and Agencies - Statewide 0016**

Initiative: Provides funding to allow enrollees to use step therapy protocols before the carrier provides coverage of prescription drugs approved by the United States Food and Drug Administration. The expanded requirements apply to health plans issued or renewed on or after January 1, 2026.

GENERAL FUND	2025-26	2026-27
All Other	\$0	\$7,176
GENERAL FUND TOTAL	<hr/> \$0	<hr/> \$7,176
HIGHWAY FUND	2025-26	2026-27
All Other	\$0	\$2,496
HIGHWAY FUND TOTAL	<hr/> \$0	<hr/> \$2,496

Amend the bill by relettering or renumbering any nonconsecutive Part letter or section number to read consecutively.

SUMMARY

This amendment replaces the bill and changes the title. With respect to coverage of a prescription drug on a carrier's formulary for the treatment of metastatic cancer and associated conditions, the amendment prohibits a health insurance carrier or utilization review organization from requiring an enrollee to use a step therapy protocol before the carrier provides coverage of a prescription drug approved by the United States Food and Drug Administration. The amendment also adds an appropriations and allocations section.

FISCAL NOTE REQUIRED

(See attached)